{
  "00872_A07_P007483_B00_A00_R1.raw": {
    "Source Name": ["P007483"],
    "Assay Name": ["P007483_R1"],
    "Raw Data File": ["00872_A07_P007483_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_C08_P008017_B00_A00_R1.raw": {
    "Source Name": ["P008017"],
    "Assay Name": ["P008017_R1"],
    "Raw Data File": ["00915_C08_P008017_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_B04_P007984_B00_A00_R2.raw": {
    "Source Name": ["P007984"],
    "Assay Name": ["P007984_R2"],
    "Raw Data File": ["00915_B04_P007984_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_B07_P007484_B00_A00_R1.raw": {
    "Source Name": ["P007484"],
    "Assay Name": ["P007484_R1"],
    "Raw Data File": ["00872_B07_P007484_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_B01_P007960_B00_A00_R1.raw": {
    "Source Name": ["P007960"],
    "Assay Name": ["P007960_R1"],
    "Raw Data File": ["00915_B01_P007960_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_A03_P007975_B00_A00_R2.raw": {
    "Source Name": ["P007975"],
    "Assay Name": ["P007975_R2"],
    "Raw Data File": ["00915_A03_P007975_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_G03_P007981_B00_A00_R1.raw": {
    "Source Name": ["P007981"],
    "Assay Name": ["P007981_R1"],
    "Raw Data File": ["00915_G03_P007981_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_E05_P007471_B00_A00_R1.raw": {
    "Source Name": ["P007471"],
    "Assay Name": ["P007471_R1"],
    "Raw Data File": ["00872_E05_P007471_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_D05_P007994_B00_A00_R2.raw": {
    "Source Name": ["P007994"],
    "Assay Name": ["P007994_R2"],
    "Raw Data File": ["00915_D05_P007994_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_B02_P007444_B00_A00_R2.raw": {
    "Source Name": ["P007444"],
    "Assay Name": ["P007444_R2"],
    "Raw Data File": ["00872_B02_P007444_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_F02_P007972_B00_A00_R2.raw": {
    "Source Name": ["P007972"],
    "Assay Name": ["P007972_R2"],
    "Raw Data File": ["00915_F02_P007972_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_C02_P007445_B00_A00_R2.raw": {
    "Source Name": ["P007445"],
    "Assay Name": ["P007445_R2"],
    "Raw Data File": ["00872_C02_P007445_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_F05_P007996_B00_A00_R1.raw": {
    "Source Name": ["P007996"],
    "Assay Name": ["P007996_R1"],
    "Raw Data File": ["00915_F05_P007996_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_E03_P007979_B00_A00_R2.raw": {
    "Source Name": ["P007979"],
    "Assay Name": ["P007979_R2"],
    "Raw Data File": ["00915_E03_P007979_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_H06_P008006_B00_A00_R1.raw": {
    "Source Name": ["P008006"],
    "Assay Name": ["P008006_R1"],
    "Raw Data File": ["00915_H06_P008006_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00892_F04_P007589_B00_A00_R1.raw": {
    "Source Name": ["P007589"],
    "Assay Name": ["P007589_R1"],
    "Raw Data File": ["00892_F04_P007589_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_C05_P007469_B00_A00_R1.raw": {
    "Source Name": ["P007469"],
    "Assay Name": ["P007469_R1"],
    "Raw Data File": ["00872_C05_P007469_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_D01_P007438_B00_A00_R2.raw": {
    "Source Name": ["P007438"],
    "Assay Name": ["P007438_R2"],
    "Raw Data File": ["00872_D01_P007438_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_F06_P007480_B00_A00_R1.raw": {
    "Source Name": ["P007480"],
    "Assay Name": ["P007480_R1"],
    "Raw Data File": ["00872_F06_P007480_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_A04_P007983_B00_A00_R2.raw": {
    "Source Name": ["P007983"],
    "Assay Name": ["P007983_R2"],
    "Raw Data File": ["00915_A04_P007983_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_C01_P007961_B00_A00_R1.raw": {
    "Source Name": ["P007961"],
    "Assay Name": ["P007961_R1"],
    "Raw Data File": ["00915_C01_P007961_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00892_A04_P007584_B00_A00_R1.raw": {
    "Source Name": ["P007584"],
    "Assay Name": ["P007584_R1"],
    "Raw Data File": ["00892_A04_P007584_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_H03_P007982_B00_A00_R2.raw": {
    "Source Name": ["P007982"],
    "Assay Name": ["P007982_R2"],
    "Raw Data File": ["00915_H03_P007982_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_H07_P008014_B00_A00_R1.raw": {
    "Source Name": ["P008014"],
    "Assay Name": ["P008014_R1"],
    "Raw Data File": ["00915_H07_P008014_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_H08_P007498_B00_A00_R1.raw": {
    "Source Name": ["P007498"],
    "Assay Name": ["P007498_R1"],
    "Raw Data File": ["00872_H08_P007498_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00892_B06_P007601_B00_A00_R1.raw": {
    "Source Name": ["P007601"],
    "Assay Name": ["P007601_R1"],
    "Raw Data File": ["00892_B06_P007601_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_B02_P007968_B00_A00_R2.raw": {
    "Source Name": ["P007968"],
    "Assay Name": ["P007968_R2"],
    "Raw Data File": ["00915_B02_P007968_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00892_D02_P007571_B00_A00_R1.raw": {
    "Source Name": ["P007571"],
    "Assay Name": ["P007571_R1"],
    "Raw Data File": ["00892_D02_P007571_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00892_G07_P007614_B00_A00_R1.raw": {
    "Source Name": ["P007614"],
    "Assay Name": ["P007614_R1"],
    "Raw Data File": ["00892_G07_P007614_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00892_H07_P007615_B00_A00_R1.raw": {
    "Source Name": ["P007615"],
    "Assay Name": ["P007615_R1"],
    "Raw Data File": ["00892_H07_P007615_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00872_B04_P007460_B00_A00_R2.raw": {
    "Source Name": ["P007460"],
    "Assay Name": ["P007460_R2"],
    "Raw Data File": ["00872_B04_P007460_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_G02_P007973_B00_A00_R2.raw": {
    "Source Name": ["P007973"],
    "Assay Name": ["P007973_R2"],
    "Raw Data File": ["00915_G02_P007973_B00_A00_R2.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R2"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00915_A01_P007959_B00_A00_R1.raw": {
    "Source Name": ["P007959"],
    "Assay Name": ["P007959_R1"],
    "Raw Data File": ["00915_A01_P007959_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  },
  "00892_D02_P007571_B00_A00_R1.raw": {
    "Source Name": ["P007571"],
    "Assay Name": ["P007571_R1_dup"],
    "Raw Data File": ["00892_D02_P007571_B00_A00_R1.raw"],
    "Characteristics[Organism]": ["human"],
    "Characteristics[MaterialType]": ["cell lines"],
    "Characteristics[CleavageAgent]": ["trypsin (Roche) at a protease‐to‐protein ratio of 1:50."],
    "Characteristics[ReductionReagent]": ["reduced with 10 mM DTT"],
    "Characteristics[AlkylationReagent]": ["alkylated using 55 mM chloroacetamide"],
    "Characteristics[NumberOfSamples]": ["65 colorectal cancer (CRC) cell lines"],
    "Characteristics[NumberOfBiologicalReplicates]": ["biological triplicates"],
    "Characteristics[TechnicalReplicate]": ["R1"],
    "Comment[Instrument]": ["Orbitrap Velos", "Orbitrap Elite"],
    "Comment[AcquisitionMethod]": ["data‐dependent acquisition"],
    "Comment[FragmentationMethod]": ["higher‐energy collisional dissociation (HCD)"],
    "Comment[FlowRateChromatogram]": ["flow rate of 300 nl/min"],
    "Comment[GradientTime]": ["turnaround time of 120 min per full proteome fraction"],
    "Comment[Separation]": ["hydrophilic strong anion exchange (hSAX) chromatography"],
    "Comment[NumberOfFractions]": ["24 fractions"],
    "Comment[IonizationType]": ["nanoflow LC‐MS/MS"],
    "Comment[MS2MassAnalyzer]": ["MS2 spectra were acquired in the Orbitrap"],
    "Comment[PrecursorMassTolerance]": ["precursor ion tolerance of 4.5 ppm"],
    "Comment[FragmentMassTolerance]": ["fragment ion tolerance was set to 20 ppm for FTMS (CRC65)", "fragment ion tolerance was set to 120 ppm for FTMS spectra"]
  }
}